Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

zongertinib (BI 1810631)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim

Drug class:

HER2 exon 20 mutation inhibitor

Related drugs:

‹

BAY 2927088 (1)

BAY 2927088 (1)

›

HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2
HER-2 overexpression	Solid Tumor	HER-2 overexpression	Solid Tumor	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2	BI 1810631 Sensitive: C2 – Inclusion Criteria BI 1810631 Sensitive : C2
HER-2 positive	Cholangiocarcinoma	HER-2 positive	Cholangiocarcinoma	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3
HER-2 positive	Esophageal Cancer	HER-2 positive	Esophageal Cancer	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3
HER-2 rearrangement	Solid Tumor	HER-2 rearrangement	Solid Tumor	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3
HER-2 mutation	Esophageal Cancer	HER-2 mutation	Esophageal Cancer	BI 1810631 Sensitive: C4 – Case Studies BI 1810631 Sensitive : C4	BI 1810631 Sensitive: C4 – Case Studies BI 1810631 Sensitive : C4
HER-2 mutation	Cholangiocarcinoma	HER-2 mutation	Cholangiocarcinoma	BI 1810631 Sensitive: C4 – Case Studies BI 1810631 Sensitive : C4	BI 1810631 Sensitive: C4 – Case Studies BI 1810631 Sensitive : C4